EUVIMEDEUVIMED entdecken
Crossref

Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers

Peyman Sheikhzadeh iD, Saeed Farzanehfar, Mehrshad Abbasi, Zeinab Bayat, Mohammadreza Abdolmaleki, Fereshteh Koosha, Nima Kasraie

Radiation Protection Dosimetry · 2025

DOI: 10.1093/rpd/ncaf059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Protection Dosimetry, 2025. Verfasst von Peyman Sheikhzadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, IKHC, Faculty of Medicine, Tehran University of Medical Sciences, Keshavarz Blvd., 1419733141, Tehran, Iran. Hauptthemen laut MEDLINE: Lutetium, Caregivers, Radiation Exposure, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Tehran University of Medical Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluates dose rates at various distances and time intervals after 177Lu-PSMA treatment and assesses caregivers’ effective doses. Dose rates were measured in 47 patients at 0.5 and 1 m up to 168 h post-injection. Initial dose rates were 34.6 ± 9 μSv (0.5 m) and 24.6 ± 5 μSv (1 m) at 5 min, peaking at 48.5 ± 15 and 31.6 ± 8 μSv at 1 h, then declining significantly over time. Caregivers’ effective doses ranged from 20 to 1170 μSv, remaining below international safety limits. This study demonstrates that patient dose rates at a distance of 1-m decline to below 30 μSv/h within 2–3 h post-injection and fall further to under 20 μSv/h after 6 h. Patients may be considered radiologically safe approximately four days post-procedure, depending on individual factors. While 177Lu-PSMA is a safe and effective PRRT modality, strict safety measures are essential to minimize exposure risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumCaregiversRadiation ExposureRadioisotopesRadiopharmaceuticalsProstatic NeoplasmsHumansMaleRadiation DosageMiddle AgedAgedFemaleRadiation ProtectionAdultProstate-Specific Antigen

Substanzen

LutetiumRadioisotopesRadiopharmaceuticalsLutetium-177PluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, IKHC, Faculty of Medicine, Tehran University of Medical Sciences, Keshavarz Blvd., 1419733141, Tehran, Iran.
  • Department of Radiation Medical Engineering, Science and Research Branch, Islamic Azad University, Hesarak, 14778-93855, Tehran, Iran.
  • Department of Radiology Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tajrish, 1989934148, Tehran, Iran.
  • Department of Radiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390, USA.

ORCID-Profile: Peyman Sheikhzadeh

Förderung

  • Tehran University of Medical Science

Zitieren

APA

Sheikhzadeh, P., Farzanehfar, S., Abbasi, M., Bayat, Z., Abdolmaleki, M., Koosha, F., & Kasraie, N. (2025). Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers. Radiation Protection Dosimetry. https://doi.org/10.1093/rpd/ncaf059

Vancouver

Sheikhzadeh P, Farzanehfar S, Abbasi M, Bayat Z, Abdolmaleki M, Koosha F, et al. Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers. Radiation Protection Dosimetry. 2025. doi:10.1093/rpd/ncaf059

BibTeX
@article{Sheikhzadeh2025,
  author = {Sheikhzadeh, Peyman and Farzanehfar, Saeed and Abbasi, Mehrshad and Bayat, Zeinab and Abdolmaleki, Mohammadreza and Koosha, Fereshteh and Kasraie, Nima},
  title = {Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers},
  journal = {Radiation Protection Dosimetry},
  year = {2025},
  doi = {10.1093/rpd/ncaf059}
}
Kostenlos starten →